Eaton Vance Management Buys 38,327 Shares of NeoGenomics, Inc. (NASDAQ:NEO)
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in NEO. Mackay Shields LLC bought a new position in shares of NeoGenomics during the 3rd quarter valued at approximately $237,000. California Public Employees Retirement System increased its position in shares of NeoGenomics by 2.5% during the 3rd quarter. California Public Employees Retirement System now owns 238,776 shares of the medical research company’s stock valued at $8,808,000 after purchasing an additional 5,800 shares during the last quarter. Aperio Group LLC increased its position in shares of NeoGenomics by 2.7% during the 3rd quarter. Aperio Group LLC now owns 50,066 shares of the medical research company’s stock valued at $1,847,000 after purchasing an additional 1,312 shares during the last quarter. Trexquant Investment LP bought a new position in shares of NeoGenomics during the 3rd quarter valued at approximately $606,000. Finally, State Board of Administration of Florida Retirement System increased its position in shares of NeoGenomics by 1.8% during the 3rd quarter. State Board of Administration of Florida Retirement System now owns 36,530 shares of the medical research company’s stock valued at $1,348,000 after purchasing an additional 660 shares during the last quarter. 91.06% of the stock is currently owned by hedge funds and other institutional investors.
Several brokerages have commented on NEO. Needham & Company LLC reaffirmed a “buy” rating and issued a $65.00 price objective on shares of NeoGenomics in a research report on Wednesday, March 3rd. BTIG Research began coverage on NeoGenomics in a research report on Friday, December 11th. They issued a “buy” rating on the stock. Truist began coverage on NeoGenomics in a research report on Wednesday, January 27th. They issued a “buy” rating and a $65.00 price objective on the stock. Craig Hallum upped their price objective on NeoGenomics from $50.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, February 25th. Finally, Morgan Stanley upped their price objective on NeoGenomics from $46.00 to $64.00 and gave the company an “overweight” rating in a research report on Wednesday, March 3rd. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the stock. NeoGenomics has an average rating of “Buy” and an average price target of $48.63.
Shares of NEO stock opened at $50.18 on Friday. The company has a current ratio of 6.54, a quick ratio of 6.22 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $5.87 billion, a price-to-earnings ratio of -1,672.11 and a beta of 0.79. NeoGenomics, Inc. has a twelve month low of $23.03 and a twelve month high of $61.57. The stock has a fifty day simple moving average of $52.50 and a two-hundred day simple moving average of $46.86.
NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings data on Wednesday, February 24th. The medical research company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.08. NeoGenomics had a positive return on equity of 0.71% and a negative net margin of 1.16%. The company had revenue of $126.00 million for the quarter, compared to the consensus estimate of $123.45 million. During the same quarter last year, the company earned $0.06 earnings per share. The firm’s revenue for the quarter was up 17.8% compared to the same quarter last year. Research analysts predict that NeoGenomics, Inc. will post -0.01 EPS for the current fiscal year.
About NeoGenomics
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States, as well as laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company’s laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
Recommended Story: Elliott Wave Theory
Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO).
Receive News & Ratings for NeoGenomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeoGenomics and related companies with MarketBeat.com’s FREE daily email newsletter.
Original Source